- Home
- CLPT vs ALT Comparison
CLPT vs ALT Comparison
Compare CLPT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | ALT |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 377.4M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CLPT | ALT |
|---|---|---|
| Price | $8.40 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $21.50 | $17.11 |
| AVG Volume (30 Days) | 668.9K | ★ 3.4M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | $41,000.00 |
| Revenue This Year | $31.18 | N/A |
| Revenue Next Year | $15.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.78 | ★ 105.00 |
| 52 Week Low | $8.27 | $1.90 |
| 52 Week High | $19.63 | $6.44 |
Technical Indicators
Market Signals| Indicator | CLPT | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 25.00 |
| Support Level | N/A | N/A |
| Resistance Level | $11.93 | $3.35 |
| Average True Range (ATR) | 0.81 | 0.14 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 5.14 | 5.17 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.